miR-130b-3p/NR3C2: a novel prognostic biomarker and drug screening target for clear cell renal cell carcinoma
Background Clear cell renal cell carcinoma (ccRCC) represents a malignancy with pronounced heterogeneity, and dependable biomarkers for predicting prognosis and therapeutic response are still scarce. MicroRNAs (miRNAs) contribute importantly to the advancement of tumors. Nevertheless, the specific function of miR-130b-3p in ccRCC is still unclear. Methods Using the TCGA-KIRC cohort, we carried out differential expression profiling and built a weighted gene co-expression network. To systematically identify miRNAs and their corresponding target genes, we developed an integrative analytical framework incorporating machine learning methodologies. Prognostic models were constructed and evaluated, while single-cell transcriptomic analysis and in vitro experiments were used to characterize the cellular and functional relevance of the selected markers. Potential therapeutic agents were explored through virtual screening and molecular docking. Results Herein, we employed both weighted gene co-expression network analysis and differential expression analysis to pinpoint miR-130b-3p and the immune-related gene NR3C2. Subsequently, we established a prognostic model incorporating miR-130b-3p and NR3C2 as core components, which showed prognostic discrimination in the analyzed cohorts. Risk stratification revealed distinct molecular characteristics, immune microenvironment profiles, and computationally inferred immune- evasion characteristics. Moreover, single-cell transcriptomic analysis characterized the cellular distribution of NR3C2, while in vitro experiments showed that miR-130b-3p inhibition increased NR3C2 mRNA expression and suppressed ccRCC cell proliferation, migration, and invasion. Finally, five putative docking-derived candidate compounds—digoxin, venetoclax, amphotericin B, ledipasvir, and natacyn—were identified through virtual screening and molecular docking. Conclusion The putative miR-130b-3p–NR3C2 relationship may have potential value for prognostic stratification and characterization of immune-related features in ccRCC. Structure-based virtual screening identified five FDA-approved compounds—digoxin, venetoclax, amphotericin B, ledipasvir, and natacyn—as putative binders of the modeled pre-miR-130b structure. These findings provide a basis for further experimental and clinical evaluation of miR-130b-3p and NR3C2 in ccRCC.
Authors
- Fangxin Chen (ORCID: https://orcid.org/0009-0003-2087-6798)
- Minyu Liu
- 喻文彬
- Guanfeng Luo
- Xiaomin Sun (ORCID: https://orcid.org/0009-0006-5029-9487)
- Liming Fan
- Xiaoshan Zhao
- Hiu Yee Kwan
- Jie Zhou
- Dexian Li
- Yanting You
- Jun Liu
Institutions
- Hong Kong Baptist University (HK)
- Zhujiang Hospital (CN)
- TCM-Intigrated Cancer Center of Southern Medical University (CN)
- Chinese People's Liberation Army (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-11-20
- DOI
- https://doi.org/10.3389/fonc.2026.1976138
- Primary Topic
- MicroRNA in disease regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00